GlassScriptPhysician profile
Haylie Tran
NPI 1225764459
$7,394.37
in general payments reported to CMS, 2019-2025
51 companies · $2,942 in 2025
The $2,942 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $677 · 2023: $1,593 · 2024: $2,182 · 2025: $2,942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,617 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,617.37 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $833.24 | 2022-2023 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $689.92 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $608.03 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $547.78 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $383.53 | 2022-2025 | Imfinzi, Saphnelo, Calquence |
| Pfizer INC. | $334.96 | 2022-2025 | |
| Daiichi Sankyo INC. | $280.76 | 2024-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $279.64 | 2024-2025 | Polivy, Tecentriq, Itovebi |
| E.R. Squibb & Sons, L.L.C. | $264.96 | 2023-2025 | Opdivo, Opdualag |
| Eisai INC. | $216.46 | 2024-2025 | |
| Gilead Sciences, INC. | $182.02 | 2023-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.02 | 2022-2025 | Gilotrif |
| Lilly USA, LLC | $172.70 | 2022-2025 | Taltz, Jaypirca, Verzenio |
| Janssen Biotech, INC. | $162.73 | 2023-2025 | Rybrevant, Tecvayli, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $161.83 | 2024-2025 | Fruzaqla, Alunbrig |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $160.60 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Puma Biotechnology, INC. | $144.01 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.37 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $113.91 | 2024-2025 | Xpovio |
| Exelixis INC. | $107.94 | 2024-2025 | Cabometyx |
| Seagen INC. | $99.99 | 2025 | |
| Horizon Therapeutics Plc | $90.11 | 2022-2023 | Krystexxa |
| Aveo Pharmaceuticals, INC. | $87.73 | 2024-2025 | |
| Boston Scientific Corporation | $80.07 | 2024-2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Emd Serono, INC. | $74.70 | 2023-2024 | Bavencio |
| Glaxosmithkline, LLC. | $74.36 | 2023-2025 | Ojjaara, Benlysta, Jemperli |
| Adc Therapeutics America, INC. | $72.49 | 2024-2025 | |
| Pharmaessentia USA Corporation | $65.32 | 2024-2025 | Besremi |
| Taiho Oncology, INC. | $56.06 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $53.58 | 2024-2025 | Onivyde, Somatuline Depot |
| Astellas Pharma US INC | $52.05 | 2024-2025 | Xtandi, Padcev |
| Adaptive Biotechnologies Corporation | $51.40 | 2024-2025 | Clonoseq |
| Sobi, INC | $50.91 | 2024 | |
| Array Biopharma INC | $47.47 | 2025 | Braftovi, Lorbrena, Xalkori |
| Radius Health, INC. | $41.64 | 2023 | Tymlos |
| Immunocore Limited | $39.01 | 2024 | Kimmtrak |
| Recordati_rare_diseases_inc. | $35.56 | 2025 | Sylvant |
| Servier Pharmaceuticals LLC | $33.38 | 2024-2025 | |
| Caris Mpi, INC. | $32.43 | 2025 | Mi Cancer Seek |
| Syndax Pharmaceuticals, INC. | $30.11 | 2025 | |
| Ucb, INC. | $29.68 | 2023 | Cimzia |
| Blueprint Medicines Corporation | $29.36 | 2024 | Ayvakit |
| Accord Healthcare, INC. | $28.27 | 2025 | |
| Stemline Therapeutics INC. | $26.56 | 2025 | Orserdu |
| Immunogen, INC. | $25.78 | 2023 | Elahere |
| Pharmacosmos Therapeutics INC. | $24.88 | 2024 | Monoferric |
| Rigel Pharmaceuticals, INC. | $24.57 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Iovance Biotherapeutics, INC. | $24.43 | 2025 | Amtagvi |
| Apellis Pharmaceuticals, INC. | $20.88 | 2025 | Empaveli |
| Telix Pharmaceuticals | $20.86 | 2023 | Illuccix |
| Coherus Oncology, INC. | $18.32 | 2025 | Loqtorzi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haylie Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.